calcyon neuron specific vesicular proteinGenealiases: DRD1IP · NSG3
Q-omics provides the consensus-scored CALY profile across patient tissues and cancer cell-line models. CALY expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CALY is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CALY RNA expression shows 14,537 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where CALY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALY survival associations across molecular data types. CALY RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALY RNA expression–survival associations across cancer types. High CALY expression shows unfavorable associations in KIRC and UVM, but favorable associations in BRCA, PAAD, SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CALY RNA expression.
This table summarizes CALY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CALY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALY shows lower tumor expression in HNSC, COAD, STAD and KICH and higher tumor expression in LIHC and BRCA. The HNSC box plot shows higher CALY RNA expression in normal versus tumor tissue (log2 FC = −0.031, t-test p = .001).
This table shows molecular features associated with CALY in patient tissues and cancer cell lines. In patient samples, CALY shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CALY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
